Cargando…

Neuroleptic Malignant Syndrome Associated with Valproate in an Adolescent

Neuroleptic malignant syndrome (NMS) is a life-threatening idiosyncratic reaction that usually occurs after the administration of antipsychotic drugs. Antidepressants, benzodiazepines, and antiepileptic drugs are also suggested to be associated with NMS. It is believed to result from a dopaminergic...

Descripción completa

Detalles Bibliográficos
Autores principales: Yıldırım, Veli, Direk, Meltem Çobanogulları, Güneş, Serkan, Okuyaz, Çetin, Toros, Fevziye
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean College of Neuropsychopharmacology 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5290716/
https://www.ncbi.nlm.nih.gov/pubmed/28138117
http://dx.doi.org/10.9758/cpn.2017.15.1.76
_version_ 1782504690694488064
author Yıldırım, Veli
Direk, Meltem Çobanogulları
Güneş, Serkan
Okuyaz, Çetin
Toros, Fevziye
author_facet Yıldırım, Veli
Direk, Meltem Çobanogulları
Güneş, Serkan
Okuyaz, Çetin
Toros, Fevziye
author_sort Yıldırım, Veli
collection PubMed
description Neuroleptic malignant syndrome (NMS) is a life-threatening idiosyncratic reaction that usually occurs after the administration of antipsychotic drugs. Antidepressants, benzodiazepines, and antiepileptic drugs are also suggested to be associated with NMS. It is believed to result from a dopaminergic blockade in the central nervous system. NMS is manifested by hyperthermia, muscle rigidity, autonomic dysfunction, altered mental status, leukocytosis, and elevated serum creatinine phosphokinase. Valproate is commonly used in the treatment of many psychiatric and neurologic disorders. Valproate can precipitate NMS, especially when used with antipsychotic drugs concurrently. A 17-year-old male patient, who presented with fever, muscular rigidity, confusion, sweating, and tachycardia was admitted to the emergency room. He had been taking only valproate for the last two months for bipolar disorder. His laboratory analyses revealed raised serum hepatic enzymes, creatinine phosphokinase, and myoglobin levels. Considering fever, rigidity, autonomic dysfunction, cognitive alteration, and high creatinine phosphokinase levels, the patient was diagnosed with NMS. In this paper, we aim to discuss the association between valproate and NMS.
format Online
Article
Text
id pubmed-5290716
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Korean College of Neuropsychopharmacology
record_format MEDLINE/PubMed
spelling pubmed-52907162017-02-06 Neuroleptic Malignant Syndrome Associated with Valproate in an Adolescent Yıldırım, Veli Direk, Meltem Çobanogulları Güneş, Serkan Okuyaz, Çetin Toros, Fevziye Clin Psychopharmacol Neurosci Case Report Neuroleptic malignant syndrome (NMS) is a life-threatening idiosyncratic reaction that usually occurs after the administration of antipsychotic drugs. Antidepressants, benzodiazepines, and antiepileptic drugs are also suggested to be associated with NMS. It is believed to result from a dopaminergic blockade in the central nervous system. NMS is manifested by hyperthermia, muscle rigidity, autonomic dysfunction, altered mental status, leukocytosis, and elevated serum creatinine phosphokinase. Valproate is commonly used in the treatment of many psychiatric and neurologic disorders. Valproate can precipitate NMS, especially when used with antipsychotic drugs concurrently. A 17-year-old male patient, who presented with fever, muscular rigidity, confusion, sweating, and tachycardia was admitted to the emergency room. He had been taking only valproate for the last two months for bipolar disorder. His laboratory analyses revealed raised serum hepatic enzymes, creatinine phosphokinase, and myoglobin levels. Considering fever, rigidity, autonomic dysfunction, cognitive alteration, and high creatinine phosphokinase levels, the patient was diagnosed with NMS. In this paper, we aim to discuss the association between valproate and NMS. Korean College of Neuropsychopharmacology 2017-02 2017-02-28 /pmc/articles/PMC5290716/ /pubmed/28138117 http://dx.doi.org/10.9758/cpn.2017.15.1.76 Text en Copyright © 2017, Korean College of Neuropsychopharmacology This is an Open-Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Report
Yıldırım, Veli
Direk, Meltem Çobanogulları
Güneş, Serkan
Okuyaz, Çetin
Toros, Fevziye
Neuroleptic Malignant Syndrome Associated with Valproate in an Adolescent
title Neuroleptic Malignant Syndrome Associated with Valproate in an Adolescent
title_full Neuroleptic Malignant Syndrome Associated with Valproate in an Adolescent
title_fullStr Neuroleptic Malignant Syndrome Associated with Valproate in an Adolescent
title_full_unstemmed Neuroleptic Malignant Syndrome Associated with Valproate in an Adolescent
title_short Neuroleptic Malignant Syndrome Associated with Valproate in an Adolescent
title_sort neuroleptic malignant syndrome associated with valproate in an adolescent
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5290716/
https://www.ncbi.nlm.nih.gov/pubmed/28138117
http://dx.doi.org/10.9758/cpn.2017.15.1.76
work_keys_str_mv AT yıldırımveli neurolepticmalignantsyndromeassociatedwithvalproateinanadolescent
AT direkmeltemcobanogulları neurolepticmalignantsyndromeassociatedwithvalproateinanadolescent
AT gunesserkan neurolepticmalignantsyndromeassociatedwithvalproateinanadolescent
AT okuyazcetin neurolepticmalignantsyndromeassociatedwithvalproateinanadolescent
AT torosfevziye neurolepticmalignantsyndromeassociatedwithvalproateinanadolescent